PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine

Clinical Trial ID NCT04353037

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04353037

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.	JAMA	2020	6.59
2	Principles and current strategies for targeting autophagy for cancer treatment.	Clin Cancer Res	2011	5.40
3	Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.	Autophagy	2014	1.98
4	Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.	Autophagy	2014	1.84
5	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.	Autophagy	2014	1.77
6	Chloroquine is a potent inhibitor of SARS coronavirus infection and spread.	Virol J	2005	1.43
7	Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.	Antimicrob Agents Chemother	2014	1.34
8	The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells.	J Virol	2006	1.17
9	SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway.	Cell Res	2008	1.11
10	Receptor recognition mechanisms of coronaviruses: a decade of structural studies.	J Virol	2014	1.09
11	Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.	Antimicrob Agents Chemother	2009	0.95